Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Varoglutamstat (PQ912) is a differentiated oral small-molecule targeting the toxic Abeta species N3pE which is being developed as disease-modifying therapy and is designed to target AD pathology upstream of Abeta-antibody focused approaches.
Lead Product(s): Varoglutamstat
Therapeutic Area: Neurology Product Name: PQ912
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Vivoryon Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2022